US 7,299,096 B2Grant

System and method for treating Parkinson's Disease and other movement disorders

Issue Date:2007-11-20

•12 Claims

•10 Drawing Sheets

Abstract

Systems and methods for treating movement disorders using cortical stimulation. In one embodiment, a method for treating movement disorders comprises determining a site at the cortex of the brain of a patient related to a movement disorder of an afflicted body part. The site can be determined by obtaining a representation of neural activity occurring in the cortex of the patient and correlating an area of neural activity with the afflicted body part. The method can also include applying neural stimulation, such as electrical or magnetic waveforms, directly to the site.

Metadata

Assignee

Northstar Neuroscience, Inc.

Inventors

Jeffrey Balzer
Allen Wyler

Application Information

Application Number:US 10/731,731

Filing Date:2003-12-09

Priority Date:2001-03-08

Art Unit:3762

Classifications

IPC:

A61N1/18

Patent Drawings (10 sheets)

Description

Cross-Reference to Related Applications

[0001] The present application is a continuation-in-part of U.S. application Ser. No. 09/802,808 filed on Mar. 8, 2001 now U.S. Pat. No. 7,010,351, and claims the benefit of U.S. Provisional Application No. 60/432,073 filed Dec. 9, 2002, both of which are herein incorporated by reference.

Technical Field

[0002] The present invention is directed toward systems and methods for treating movement disorders, such as Parkinson's Disease, that are associated with abnormal neural activity in the brain.

Background

[0003] A wide variety of mental and physical processes are controlled or influenced by neural activity in particular regions of the brain. For example, various physical or cognitive functions are directed or affected by neural activity within the sensory or motor cortices. Across most individuals, particular areas of the brain appear to have distinct functions. In the majority of people, for example, the areas of the occipital lobes relate to vision; the regions of the left interior frontal lobes relate to language; portions of the cerebral cortex appear to be consistently involved with conscious awareness, memory, and intellect; and particular regions of the cerebral cortex, the basal ganglia, the thalamus, and the motor cortex cooperatively interact to facilitate motor function control.

[0004] Many problems or abnormalities with body functions can be caused by damage, disease, and/or disorders in the brain. For example, Parkinson's Disease (PD) is related to the degeneration or death of dopamine producing neurons in the substantia nigra region of the basal ganglia in the brain. Dopamine is a neurotransmitter that transmits signals between areas of the brain. As the neurons in the substantia nigra deteriorate, the reduction in dopamine causes abnormal neural activity that results in a chronic, progressive deterioration of motor function control. Conservative estimates indicate that PD may affect more than one million individuals in the United States alone.

[0005] PD patients typically exhibit one or more of four primary symptoms. One primary symptom is a tremor in an extremity (e.g., a hand) that occurs while the extremity is at rest. Other primary symptoms include a generalized slowness of movement (bradykinesia); increased muscle rigidity or stiffness (rigidity); and gait or balance problems (postural dysfunction). In addition to or in lieu of these primary symptoms, PD patients may exhibit secondary symptoms including: difficulty initiating or resuming movements; loss of fine motor skills; lack of arm swing on the affected side of the body while walking; foot drag on the affected side of the body; decreased facial expression; voice and/or speech changes; cognitive disorders; feelings of depression or anxiety; and/or other symptoms.

[0006] Effectively treating PD or other movement disorders related to neurological conditions can be very difficult. Current treatments for PD symptoms include drugs, ablative surgical intervention, and/or neural stimulation. Drug treatments or therapies may involve, for example, the administration of a dopamine precursor that is converted to dopamine within the central nervous system (i.e., Levodopa (L-dopa)). Other types of drug therapies are also available. Unfortunately, drug therapies frequently become less effective or ineffective over time for an undesirably large patient population. A PD patient may require multiple drugs in combination to extend the time period of efficacy of drug therapies. Drug treatments additionally have a significant likelihood of inducing undesirable physical side effects; motor function complications such as uncontrollable involuntary movements (dyskinesias) are a particularly common side effect. Furthermore, drug treatments may induce undesirable cognitive side effects such as confusion and/or hallucinations.

[0007] Ablative surgical intervention for PD typically involves the destruction of one or more neural structures within the basal ganglia or thalamus that have become overactive because of the lack of dopamine. Unfortunately, such neural structures reside deep within the brain, and hence ablative surgical intervention is a very time consuming and highly invasive procedure. Potential complications associated with the procedure include risk of hemorrhage, stroke, and/or paralysis. Moreover, because PD is a progressive disease, multiple deep brain surgeries may be required as symptoms progressively worsen over time. Although ablative surgical intervention may improve a PD patient's motor function, it is not likely to completely restore normal motor function. Furthermore, since ablative surgical intervention permanently destroys neural tissue, the effects of such intervention cannot be readily adjusted or “fine tuned” over time.

[0008] Neural stimulation treatments have shown promising results for reducing some of the symptoms associated with PD. Neural activity is governed by electrical impulses or “action potentials” generated in and propagated by neurons. While in a quiescent state, a neuron is negatively polarized and exhibits a resting membrane potential that is typically between −70 and −60 mV. Through chemical connections known as synapses, any given neuron receives excitatory and inhibitory input signals or stimuli from other neurons. A neuron integrates the excitatory and inhibitory input signals it receives, and generates or fires a series of action potentials in the event that the integration exceeds a threshold potential. A neural firing threshold, for example, may be approximately −55 mV. Action potentials propagate to the neuron's synapses and are then conveyed to other synaptically connected neurons.

[0009] Neural activity in the brain can be influenced by neural stimulation, which involves the application of electrical and/or magnetic stimuli to one or more target neural populations within a patient using a waveform generator or other type of device. Various neural functions can thus be promoted or disrupted by applying an electrical current to one or more regions of the brain. As a result, researchers have attempted to treat certain neurological conditions, including PD, using electrical or magnetic stimulation signals to control or affect brain functions.

[0010] Deep Brain Stimulation (DBS) is a stimulation therapy that has been used as an alternative to drug treatments and ablative surgical therapies. In DBS, one or more electrodes are surgically implanted into the brain proximate to deep brain or subcortical neural structures. For treating PD or other movement disorders, the electrodes are positioned in or proximate to the ventrointermediate nucleus of the thalamus; basal ganglia structures such as the globus pallidus internalis (GPi); or the Subthalamic Nucleus (STN). The location of the stimulation site for the electrodes depends upon the symptoms that a patient exhibits and the severity of the symptoms.

[0011] In a typical DBS system, a pulse generator delivers a continuous or essentially continuous electrical stimulation signal having a pulse repetition frequency of approximately 100 Hz to each of two deep brain electrodes. The electrodes are may be positioned bilaterally on the left and right sides of the brain relative to particular neural structures such as those indicated above. U.S. Pat. No. 5,883,709 discloses one conventional DBS system for treating movement disorders.

[0012] Although DBS therapies may significantly reduce one or more PD symptoms, particularly when combined with drug treatments, they are highly invasive procedures. In general, configuring a DBS system to properly function within a patient requires two time consuming, highly invasive surgical procedures for implanting the DBS electrodes. Each such surgical procedure has essentially the same risks as those described above for ablative surgical intervention. Moreover, DBS may not provide relief from some movement disorders.

[0013] Motor Cortex Stimulation (MCS) is another type of brain stimulation treatment that has been proposed for treating Parkinson's Disease. MCS involves the application of stimulation signals to the motor cortex of a patient. One MCS system includes a pulse generator connected to a strip electrode that is surgically implanted over a portion of only the motor cortex (precentral gyrus). The use of MCS to treat PD symptoms is described in Canavero, Sergio, Extradural Motor Cortex Stimulation for Advanced Parkinson's Disease: Case Report, Movement Disorders (Vol. 15, No. 1, 2000).

[0014] Because MCS involves the application of stimulation signals to surface regions of the brain rather than deep neural structures, electrode implantation procedures for MCS are significantly less invasive and time consuming than those for DBS. As a result, MCS may be a safer and simpler alternative to DBS for treating PD symptoms. Present MCS techniques, however, fail to address or adequately consider a variety of factors that may enhance or optimize the extent to which a patient experiences short term and/or long term relief from PD symptoms.

Brief Description of the Drawings

[0015] FIG. 1 is a flow chart illustrating methods for treating movement disorders in accordance with several embodiments of the invention.

[0016] FIG. 2A is an image showing a mid saggital section of a brain of a patient.

[0017] FIG. 2B is an image showing an axial view of a portion of the cerebral cortex of the brain of the patient.

[0018] FIG. 3A is a side view of a brain of a patient with an electrode array implanted in accordance with one embodiment of the invention.

[0019] FIG. 3B is a side view of a brain of a patient with an electrode array implanted in accordance with another embodiment of the invention.

[0020] FIG. 3C is a lateral cross-sectional view of the cortex of a patient showing additional stimulation sites in accordance with additional embodiments of the invention.

[0021] FIG. 4 is a side view of a brain of a patient showing one embodiment of applying neural stimulation to treat movement disorders.

[0022] FIG. 5 is a cross-sectional view of the cerebral cortex of a patient illustrating another embodiment of treating movement disorders in accordance with the invention.

[0023] FIG. 6 is a schematic view illustrating a system for treating movement disorders in accordance with the invention.

[0024] FIGS. 7–9 are flow charts of methods in accordance with embodiments of the invention for treating movement disorders.

Detailed Description

[0025] The following disclosure describes several embodiments and systems for treating PD and other movement disorders using cortical stimulation. Several embodiments and features of methods and systems for treating PD in accordance with the invention are set forth and described in FIGS. 1–6. Additional embodiments and features of methods and systems for treating movement disorders, including PD, are set forth and described in FIGS. 7–9. It will be appreciated that other embodiments in accordance with the invention can include additional procedures or different features than those shown in FIGS. 1–9. Additionally, several embodiments of methods and systems in accordance with the invention may not include all of the features shown in these figures. Additionally, like reference numbers refer to similar or identical components or procedures throughout the figures.

A. Embodiments for Treating PD

[0026] FIG. 1 is a flow chart illustrating several methods for treating movement disorders in accordance with embodiments of the invention. The methods shown in FIG. 1 are particularly useful for treating PD. In one embodiment, a method 100 for treating movement disorders includes an imaging procedure 102 in which an image of the relative position between external markers and at least one of the central sulcus, precentral gyrus, and/or the postcentral gyrus of a patient is provided. The external markers can be anatomical features of the patient or fiducials that are attached to the patient. For example, the external markers can be fiducials that are attached to the skull of the patient. The method 100 also includes a site selection procedure 104 that involves identifying a stimulation site relative to the external markers using the images obtained in the imaging procedure 102. The stimulation site is generally proximate to the dura of the patient and over at least the precentral gyrus of the cortex. As explained in more detail below, the stimulation site can also be located over the central sulcus and/or the postcentral gyrus of the patient. The imaging procedure 102 and the site selection procedure 104 result in an accurate determination of the location of the underlying cortical features relative to external landmarks on the patient. As explained in more detail below, this is expected to significantly improve the efficacy of stimulation therapies for treating PD and other movement disorders.

[0027] The method 100 can further include a stimulating procedure 110 in which neural stimulation is applied directly to the stimulation site. The neural stimulation can be an electrical current applied epiduraly or subduraly to the stimulation site. When the neural stimulation is an electrical current applied directly to the cerebral cortex proximate to the dura, the method 100 includes an implanting procedure 108 in which an electrode is implanted at least proximate to the dura at the stimulation site. The implanting procedure 108 accordingly occurs after the site selection procedure 104 and before the stimulating procedure 110. In other embodiments, the neural stimulation of the stimulating procedure 110 can be transcutaneous magnetic stimulation. Several aspects of each of the procedures 102–110 are described in more detail below with respect to FIGS. 2A–5.

[0028] FIGS. 2A and 2B are examples of images provided by the imaging procedure 102 (FIG. 1) for use in the site selection procedure 104 (FIG. 1). The imaging procedure 102 can be Magnetic Resonance Imaging (MRI), CT imaging, fMRI imaging or other suitable processes. FIG. 2A is a magnetic resonance image 200a showing the brain 210 of a patient P along a mid saggital section. The image 200a shows the location of various features of the cerebral cortex 220 relative to fiducial markers 230 attached to the skull of the patient P. One embodiment of the site selection procedure 104 involves locating the pars marginalis sulcus 240 of the cortex 220 using the image 200a of the mid saggital section. This particular image is useful because the pars marginalis sulcus is the only sulcus that can be followed into the interhemispheric fissure in this view. Based on the location of the pars marginalis sulcus shown in image 200a, this position can be extrapolated to an axial image to determine the location of the central sulcus, the postcentral gyrus, and the precentral gyrus on the cortex 220 relative to the external markers.

[0029] The site selection procedure 104 (FIG. 1) continues with an axial image of the cortex 220. FIG. 2B is a magnetic resonance image 200b of a brain taken along an axial section. Referring to FIG. 2B, the pars marginalis sulcus 240 appears as a small, symmetrical sulcus extending bilaterally out from the interhemispheric fissure. Based upon the position of the pars marginalis sulcus 240, the position of the postcentral sulcus 242 can be determined by moving laterally (i.e., outward) from the pars marginalis sulcus 240. The postcentral sulcus 242 forms the posterior boundary of the postcentral gyrus 260, and thus the central sulcus 244 can be identified as the anterior boundary of the postcentral gyrus 260. Similarly, the central sulcus 244 forms the posterior boundary of the precentral gyrus 250 and the precentral sulcus 246 forms the anterior boundary of the precentral gyrus 250.

[0030] The site selection procedure 104 can also involve identifying an external region on the patient relative to the location of the central sulcus 244. After identifying the location of the central sulcus 244 on the image 200b, the location of the central sulcus 244 is noted relative to the external markers 230. Using standard neuronavigational MRI techniques, the data from the images can be transferred into an intraoperative navigational station that locates the external position on the scalp of the patient overlying the central sulcus 244 relative to the position of the fiducial markers 230. The external position accordingly defines the general area where stimulation will be applied. The actual stimulation site is generally under the scalp at an area that is proximate to the dura of the patient and aligned with the external position identified on the patient.

[0031] FIGS. 3A–3C illustrate several embodiments of the implanting procedure 108 for implanting electrodes at a stimulation site. FIG. 3A, more specifically, is a schematic side view of the brain 200 illustrating one embodiment of implanting a linear electrode array 310 at a stimulation site 300a proximate to the dura and over the precentral gyrus 250. In this embodiment, the linear electrode array 310 has a plurality of electrodes 320 arranged along a single row, but in other embodiments the linear electrode array 310 may have only one electrode 320. For example, the electrode array 310 can have only a single electrode 320 (i.e., a contact) instead of an array of electrodes. The electrodes 320 can be circular contacts each having a surface area of approximately 5 mm²and being spaced apart by about 7.5 mm. In other embodiments, the electrodes can be other shapes and have other configurations, such as an elongated electrode. The linear electrode array 310 has a lead 322 coupled to the electrodes 320 and an implanted pulse generator implanted above the neck or at a subclavicular location. The lead 322 is tunneled through the patient using standard techniques.

[0032] The linear electrode array 310 can be positioned so that the row of electrodes 320 extends in a medial to lateral direction generally parallel with the central sulcus 244. The electrodes 320 are also superimposed over the precentral gyrus 250. The linear electrode array 310 generally has a plurality of electrodes 320 to provide extensive coverage over the precentral gyrus 250 and thus activate a large number of neurons in the motor cortex (e.g., use all of the electrodes) or only discrete populations of neurons in the motor cortex with only a single implantation of an electrode array (e.g., activate only selected electrodes). The electrode array 310 can be implanted so that the electrodes are proximate to the dura such as at an epidural or subdural location.

[0033] FIG. 3B is a side-view of the brain 200 illustrating another embodiment for implanting an electrode array proximate to the dura at the stimulation site. In this embodiment, the stimulation site 300b is located over the precentral gyrus 250 and the postcentral gyrus 260. A grid electrode array 330 is implanted at the stimulation site 300b proximate to the dura. The grid electrode array 330 can include a plurality of first electrodes 340a arranged along a first row and a plurality of second electrodes 340b arranged along a second row. The first and second rows of electrodes 340a–b can extend generally at an oblique angle relative to the central sulcus 244. The grid electrode array 330 also has a lead 342 coupled to the electrodes 340a–b and an implanted pulse generator. As with the linear electrode array 310, the grid electrode array 330 can be implanted so that the electrodes are proximate to the dura.

[0034] One aspect of several embodiments of the invention is that the stimulation sites 300a and 300b shown on FIGS. 3A and 3B are located relative to the precentral gyrus, the central sulcus 244, and/or the postcentral gyrus 260 using the imaging and site selection procedures 102–104 described above with respect to FIGS. 2A and 2B. This enables the stimulation to be applied to desired locations on the cortex with much greater accuracy than previous methods that rely solely on the external anatomical features of the patient. The greater precision of locating the stimulation sites 300a–b for implanting the electrode arrays is expected to significantly enhance the efficacy of stimulation treatments for treating PD and other movement disorders.

[0035] Another aspect of several embodiments is that the efficacy of the stimulation treatment can also be enhanced by locating the stimulation sites 300a–b at a desired superior-inferior location along the precentral gyrus and/or the postcentral gyrus relative to the sylvian fissure and the interhemispherical fissure. FIG. 3C, for example, is a lateral section view taken along line 3C—3C of FIG. 3B. The stimulation site can be located more towards the sylvian fissure 370 for treating predominant symptoms of speech disorders or towards the interhemispherical fissure 380 for treating predominant symptoms of gait disorders. The superior-inferior location along the precentral gyrus 250 and/or the postcentral gyrus 260 can accordingly be predicated by the symptomotology of the function that is affected by the movement disorder.

[0036] FIG. 4 is a side view illustrating several embodiments of applying neural stimulation directly to the stimulation site. More specifically, FIG. 4 illustrates the grid electrode array 330 positioned at the stimulation site 300b over the precentral gyrus 250, the central sulcus 244, and the postcentral gyrus 260. The neural stimulation can comprise passing an electrical current through the electrodes 340a–b to the stimulation site 300b. In one embodiment, the electrical current can be applied to a single one of the electrodes 340a or 340b to provide a monopolar pulse of current to a small area of the cortex 220. A return electrode can be positioned elsewhere in the patient, such as on the other side of the patient's brain or at a subclavicular location. The return electrode can be a portion of a pulse generator or another electrode implanted elsewhere in the patient. In other embodiments, electrical current can be passed through all of the electrodes 340a–b or only a subset of these electrodes to activate larger or different populations of neurons. In these embodiments, the potential applied to the electrodes 340a–b can be the same across all of the activated electrodes to provide monopolar stimulation at the stimulation site. This embodiment also typically has a return electrode implanted elsewhere in the patient as explained above. In other embodiments, some of the electrodes can be biased with a positive polarity and other electrodes can be biased with a negative polarity. For example, the first electrodes 340a can be biased with one polarity and the second electrodes 340b can be biased with an opposite polarity. This embodiment provides a bipolar stimulation to the cortex 220. The particular configuration of the electrodes can be optimized after implantation to provide the most efficacious therapy for the patient.

[0037] The particular waveform of the stimuli depends upon the symptoms of the particular patients. In one embodiment, the stimulus can have a waveform with a current of approximately 0.5 mA to 10 mA, a pulse duration of approximately 20 microseconds–500 milliseconds, and a frequency of approximately 10 Hz–200 Hz. In other embodiments, the electrical stimulus can have a current of approximately 3 mA to 8 mA, a pulse duration of 100 microseconds–200 microseconds, and a frequency of approximately 20 Hz–50 Hz. In still other embodiments, the current can be approximately 4 mA to 6 mA, and more particularly approximately around 5 mA. The waveforms of any of the foregoing embodiments can have a voltage of approximately: 0.25 V to 5.0 V in many applications; 0.5 V to 3.5 V in more specific applications; 2.0 V to 3.5 V in still more specific applications; and 3.0V in a particular application. Additionally, the pulse duration can be in the range of 90–180 microseconds. The stimulus can be applied for a period of 0.5 hour–4.0 hours, and in many applications the therapy is applied for a period of approximately 0.5 hour–1.5 hours. In other embodiments, the stimulation can be applied continuously, or only during waking periods but not sleeping periods. Examples of specific stimulation protocols for use with an electrode array at an epidural stimulation site over the precentral gyrus are as follows:

Example 1

- [0038] An electrical stimulus having a current of approximately 0.1 mA to 10 mA, an impedance of 600 to 1000 Ohms, a pulse duration of 160 microseconds, and a frequency of approximately 130 Hz. The therapy is not applied continuously, but rather during 30–60 minute intervals.

Example 2

- [0039] The stimulus has a current of approximately 0.1 mA to 10 mA, a pulse duration of approximately 150–180 microseconds, and a frequency of approximately 25 Hz–31 Hz. The stimulus is applied continuously during waking periods, but it is discontinued during sleeping periods to conserve battery life of the implanted pulse generator.

Example 3

- [0040] The stimulus has a current of approximately 2 mA to 4 mA, a pulse duration of approximately 90 microseconds, and a frequency of approximately 30 Hz. This stimulus is applied continuously during waking and sleeping periods, but it can be discontinued during sleeping periods.

[0041] FIG. 5 illustrates another aspect of an embodiment of the invention. In many cases of PD, the symptoms are manifested to a greater extent on one side of the body than the other. For example, a patient may have a tremor in both hands, but usually one hand will have a tremor worse than the other hand. In this embodiment, the patient's body is divided into a first side and a second side opposite the first side relative to a medial axis (e.g., right side-left side), and only one side of the cortex is stimulated to treat the disorder on both sides of the body. This embodiment can be carried out by implanting the electrode array 320 or 330 at a stimulation site on only the first side of the patient when the disorder of a motor function is greater on the second side of the patient. For example, this embodiment can also include implanting one or more electrodes at a homologous location on the contralateral hemisphere relative to the movement disorder. The single electrode array can provide a bilateral affect that not only treats the disorder associated with the second side of the patient, but also treats the disorder associated with the first side of the patient. For example, if the patient experiences a bilateral tremor that is worse on the right side compared to the left side, then an electrode array can be implanted proximate to the dura over only the left hemisphere of the cortex 220. The bilateral effect of the single-side stimulation may be enhanced using monopolar stimulation techniques in which the electrodes are biased with the same polarity. The bilateral effect may be caused by activation of commissural neurons (large pyramidal cells) in the deep portion of layer III of the motor cortex. Subsequent to activation, these neurons can depolarize complimentary cell groups in the contralateral hemisphere via the corpus callosum.

[0042] In a specific embodiment, by accurately locating the electrodes over the precentral gyrus using the imaging and site selection procedures 102 and 104 described above, the electrode may maximally effect the contralateral lower extremity musculature and also the ipsilateral muscle groups. It is expected that the placement should be sufficiently remote from the interhemispheric fissure to avoid venous damage or occlusion. As a result, the single-side stimulation site may be particularly advantageous in certain situations because it requires only a single electrode array to be planted relative to a single hemisphere of the cortex 220 of the patient. This reduces the invasiveness and the risk associated with surgery.

[0043] FIG. 5 also illustrates another embodiment in which an electrode array 330a (shown in broken line) is implanted at a site on the ipsilateral hemisphere of the brain relative to the side of the body most affected by the movement disorder. The electrode array 330a can be implanted by itself such that it is the only electrode array. In a different embodiment, however, both of the electrode arrays 330 and 330a can be implanted at homologous and/or non-homologous regions relative to the movement disorders on both hemispheres of the brain. Additionally, the electrode array 330a can have only a single electrode as described above with respect to the electrode array 330.

[0044] FIG. 6 is a schematic view illustrating embodiments of systems for treating movement disorders in accordance with the invention. The system can include the linear electrode array 310 coupled to an implanted pulse generator 600a implanted at a subclavicular location in the patient P. The grid electrode array 330 can be substituted for the linear electrode array 310. In either of these embodiments, a lead 322/342 is tunneled between the implanted pulse generator 600a and the electrode array. In another embodiment, the system has an implanted above-neck pulse generator 600b that is smaller and configured to be implanted at a location above the neck of the patient P. The above-neck implanted pulse generator 600b can be planted posteriorly of the ear of the patient P. In each of these embodiments, the electrode arrays 310 or 330 (not shown in FIG. 6) are implanted underneath the scull S of the patient P at an epidural or subdural stimulation site as set forth above.

B. Embodiment for Treating Movement Disorders

[0045] FIG. 7 is a flow chart illustrating additional methods for treating movement disorders in accordance with additional embodiments of the invention. In one embodiment, a method 700 includes a site selection procedure 710 including determining a cortical site related to a movement disorder of an afflicted body part of the patient. In one embodiment, the site selection procedure 710 includes obtaining a representation of neural activity occurring in the cortex of the patient, and correlating an area of neural activity with the afflicted body part. In a related embodiment, the site selection procedure 710 can include providing a representation of neural activity in the cortex of the brain of a patient, identifying a neural activation area on the representation considered to be related to a body part of the patient affected by a movement disorder, and selecting the cortical site on the patient by referencing the identified neural activation area to the anatomy of the patient.

[0046] In patients having little or no tremor symptoms, a representation of neural activity occurring in the cortex can be obtained or provided by imaging neural activity in the cortex using a neural imaging technique while performing a task related to the affected body part. For example, the representation of neural activity in the cortex can be obtained by imaging cortical neural activity while (a) the patient mentally concentrates on moving the affected body part, (b) the affected body part is moved by the patient, (c) an electrical pulse is applied to the affected body part, and/or (d) another person or device passively moves the affected body part. In other embodiments, obtaining a representation of neural activity in the brain can include collecting data of neural activity in the cortex of the patient related to the affected body part without necessarily generating an image. The collected data can be stored in a memory and processed to generate anatomical coordinates and/or an image of the neural activity.

[0047] The site selection procedure 710 is expected to increase the efficacy of the stimulation therapy and provide additional benefits. For example, having the patient concentrate on moving the affected body part or actually move the affected body part while imaging the neural activity in the cortex is expected to provide an accurate indication of the area(s) in the cortex where neural activity for controlling the motor function of the affected body part is performed. Similarly, applying an electrical pulse to the affected body part while imaging neural activity in the cortex is expected to provide another accurate indication of where neural activity occurs for controlling the motor function of the affected body part. By providing an accurate indication of the location of neural activity related to the affected body part, the method 700 is expected to operate at low electrical potentials to reduce unwanted collateral stimulation of neurons and prolong the battery life of an implanted pulse generator. Moreover, such precise location of the electrodes enhances the efficacy of the stimulation procedure because the neurons that are involved in controlling the affected body part are more likely to be stimulated in a controlled manner.

[0048] The method 700 further includes a stimulation procedure 720 that involves applying neural stimulation directly to the cortical site. The stimulation procedure can be preceded by implanting an electrode unit proximate to the dura mater at the cortical site. The electrode unit can have a single electrode or an array with a plurality of electrodes as explained above. The stimulation procedure 720 can include any of the electrical waveforms set forth above. In additional embodiments, the stimulation procedure can include applying an electrical waveform having a frequency of approximately 5–1000 Hz. In more specific embodiments, the stimulation procedure 720 can include applying an electrical waveform having a frequency of approximately 10–60 Hz, and more specifically at a frequency of 20 Hz or 50 Hz. Other examples could be at higher frequencies of 90–150 Hz or in a narrower range of 100–120 Hz.

[0049] FIG. 8 is a flow chart illustrating another method for treating movement disorders in accordance with additional embodiments of the invention. In one embodiment, the method 800 includes performing a craniotomy 810 to expose a cortical location related to an affected body part. The craniotomy 810 can expose subdural or epidural tissue. The method 800 further includes a test procedure 820 and a mapping procedure 830. The test procedure 820 includes applying a test stimulation waveform to a plurality of discrete regions of the cortical location. In one embodiment of the test procedure 820, a single electrode is moved to different discrete locations of the cortical region exposed by the craniotomy and an electrical pulse is applied to each location separately. In other embodiments, the test procedure 820 includes implanting an electrode array having a plurality of electrodes such that each electrode is adjacent to a discrete region of the cortical location. This embodiment includes applying the test stimulation waveform separately to one or more of the individual electrodes in different combinations. Both of these embodiments of the test procedure 820 apply the test stimulation waveform to the discrete regions of the cortical location at separate time periods. The mapping procedure 830 includes (a) verifying the proper electrode location and/or (b) measuring the efficacy of the test stimulation waveforms as they are applied to the different discrete regions of the cortical location. The mapping procedure can occur while the patient is under an anesthetic, and it can also apply electrical pulses at a current that is sufficient to provoke a response. After verifying the electrode location during surgery, the mapping procedure 830 can further include monitoring the decrease and/or increase in the tremor of a body part affected by PD as the test waveform is applied to the different discrete regions. The method 800 further includes a selection procedure 840 in which one or more of the discrete regions is selected based upon the efficacy of the discrete regions for treating the movement disorder. The selection procedure 840 accordingly determines which electrode(s) receive electrical pulses for treating the movement disorder. The method 800, accordingly, further includes a stimulation procedure 850 including applying a therapy stimulation waveform to the selected regions of the cortical location.

[0050] FIG. 9 is a flow chart of another method 900 for treating movement disorders in accordance with another embodiment of the invention. The method 900 includes an implanting procedure 910 in which an electrode is implanted at a cortical stimulation site based upon a standard correlation between cortical-neural activity and motor functions in humans. For example, an electrode array can be implanted at a cortical stimulation site based upon the standard correlation between cortical neural activity and motor functions in humans, and in particular the standard location for neural activity in humans for motor control of the affected body part. The implanting procedure 910 accordingly does not necessarily need to select the stimulation site based upon an image, data or other information to obtain or provide a representation of neural activity in the brain related to the affected body part. The method 900 further includes a stimulation procedure 920 involving applying electrical stimulation to the cortical location to treat a movement disorder.

[0051] From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the spirit and scope of the invention. For example, the leads of the electrode arrays may be coupled to an external pulse generator instead of an implanted pulse generator. In an alternate embodiment, the stimulation site can be selected at an area of the cortex that is not normally associated with the function of the body part(s) affected by the movement disorder (e.g., non-homologous regions). This embodiment accordingly places the electrodes at other neurofunctional areas that control other movement and/or speech functions. In still other embodiments, electrode arrays having different configurations of electrodes can be implanted on opposing hemispheres of the cortex. Furthermore, in an additional embodiment, transcutaneous magnetic stimulation can be applied to the selected stimulation site before implanting the electrodes to estimate the response and refine the location of the stimulation site. For example, a stimulation site can be selected using an imaging modality (e.g., MRI, fMFI, etc.) and/or externally estimating the site according to the normal location for neural activity associated with the movement disorder, and then transcutaneous magnetic stimulation can be applied at the stimulation site and/or neighboring areas before implanting the electrode. The precise location for the stimulation site can then be modified according to the results of the transcutaneous magnetic stimulation in a manner similar to the mapping procedure 830 described above. Accordingly, the invention is not limited except as by the appended claims.

Claims

Certificate of Correction present

The claims shown below may not include correction changes. Use the corrected PDF for authoritative text.

We claim:

1. A method for treating movement disorders, comprising:

implanting an electrode array having a plurality of first electrodes arranged in a first row and a plurality of second electrodes arranged in a second row at a stimulation site over the central sulcus of the patient; and applying an electrical signal to at least some of the first electrodes and/or the second electrodes, wherein the patient has a movement disorder that is worse on a first side of the patient than on a second side of the patient opposite the first side, and wherein implanting the electrode array comprises positioning the electrode array over the precentral gyrus on the second side of the patient only.

2. A method for treating a patient having a movement disorder that is worse on a first side of the patient than on a second side of the patient opposite the first side; comprising:

implanting an electrode at a stimulation site located over at least a portion of the precentral gyrus of the patient on only the second side of the patient; and

applying stimulation to the electrode to treat the movement disorder on both the first side and the second side of the patient.

3. The method of claim 2 wherein implanting the electrode comprises positioning an array having a plurality of electrodes over only the precentral gyrus of the patient.

4. The method of claim 2 wherein implanting the electrode comprises positioning an array having a plurality of electrodes such that at least one electrode is over the precentral gyrus and at least one other electrode is over the postcentral gyrus of the patient on only the second side of the patient.

5. The method of claim 2, wherein implanting the electrode comprising placing an array having a plurality of first electrodes arranged in a first row and a plurality of second electrodes arranged in a second row at the stimulation site.

6. The method of claim 5 wherein implanting the electrode array comprises positioning the first and second rows at an oblique angle relative to the central sulcus of the patient.

7. The method of claim 5 wherein implanting the electrode array comprises positioning one of the first electrodes and one of the second electrodes over the precentral gyrus of the patient, and positioning another one of the first electrodes and another one of the second electrodes over the postcentral gyrus of the patient.

8. The method of claim 2 wherein applying stimulation to the electrode comprises delivering an electrical current directly to the dura of the patient at the stimulation site.

9. The method of claim 2 wherein applying stimulation to the electrode comprises delivering an electrical current directly to the patient at least proximate to the dura over the stimulation site.

10. The method of claim 9 wherein delivering an electrical current directly to the patient comprises applying a unipolar electrical potential to the electrode implanted at the stimulation site.

11. The method of claim 9 wherein delivering an electrical current directly to the patient comprises applying a unipolar electrical potential to a plurality of electrodes implanted at the stimulation site.

12. The method of claim 9 wherein delivering an electrical current directly to the patient comprises applying a bipolar electrical potential to a plurality of electrodes implanted at the stimulation site.

Patent Citations (300)

Patent	Date	Inventor	Cited By
US2716226(A)	1955-08-01	Jonas	Applicant
US2721316(A)	1955-10-01	Shaw	Applicant
US3628193(A)	1971-12-01	Collins	Applicant
US3650276(A)	1972-03-01	Burghele et al.	Applicant
US3850161(A)	1974-11-01	Liss	Applicant
US3918461(A)	1975-11-01	Cooper	Applicant
US4030509(A)	1977-06-01	Heilman et al.	Applicant
US4125116(A)	1978-11-01	Fischell	Applicant
US4140133(A)	1979-02-01	Kastrubin et al.	Applicant
US4214804(A)	1980-07-01	Little	Applicant
US4245645(A)	1981-01-01	Arseneault et al.	Applicant
US4308868(A)	1982-01-01	Jhabvala	Applicant
US4328813(A)	1982-05-01	Ray	Applicant
US4340038(A)	1982-07-01	McKean	Applicant
US4431000(A)	1984-02-01	Butler et al.	Applicant
US4474186(A)	1984-10-01	Ledley et al.	Applicant
US4542752(A)	1985-09-01	Dehaan	Applicant
US4590946(A)	1986-05-01	Loeb	Applicant
US4607639(A)	1986-08-01	Tanagho	Applicant
US4646744(A)	1987-03-01	Capel	Applicant
US4702254(A)	1987-10-01	Zabara	Applicant
US4844075(A)	1989-07-01	Liss	Applicant
US4865048(A)	1989-09-01	Eckerson	Applicant
US4869255(A)	1989-09-01	Putz	Applicant
US4903702(A)	1990-02-01	Putz	Applicant
US4969468(A)	1990-11-01	Byers et al.	Applicant
US5002053(A)	1991-03-01	Garcia-Rill	Applicant
US5024226(A)	1991-06-01	Tan	Applicant
US5031618(A)	1991-07-01	Mullett	Applicant
US5044368(A)	1991-09-01	Putz	Applicant
US5054906(A)	1991-10-01	Lyons, Jr.	Applicant
US5063932(A)	1991-11-01	Dahl et al.	Applicant
US5092835(A)	1992-03-01	Schurig	Applicant
US5121754(A)	1992-06-01	Mullett	Applicant
US5143089(A)	1992-09-01	Alt	Applicant
US5169384(A)	1992-12-01	Bosniak	Applicant
US5184620(A)	1993-02-01	Cudahy et al.	Applicant
US5193540(A)	1993-03-01	Schulman et al.	Applicant
US5215086(A)	1993-06-01	Terry	Applicant
US5215088(A)	1993-06-01	Normann et al.	Applicant
US5224491(A)	1993-07-01	Mehra	Applicant
US5255678(A)	1993-10-01	Deslauriers	Applicant
US5263967(A)	1993-11-01	Lyons, III et al.	Applicant
US5269303(A)	1993-12-01	Wernicke et al.	Applicant
US5271417(A)	1993-12-01	Swanson et al.	Applicant
US5282468(A)	1994-02-01	Klepinski	Applicant
US5299569(A)	1994-04-01	Wernicke et al.	Applicant
US5303705(A)	1994-04-01	Nenov	Applicant
US5304206(A)	1994-04-01	Baker	Applicant
US5314458(A)	1994-05-01	Najafi et al.	Applicant
US5358513(A)	1994-10-01	Powell	Applicant
US5370672(A)	1994-12-01	Fowler	Applicant
US5405375(A)	1995-04-01	Ayers et al.	Applicant
US5406957(A)	1995-04-01	Tansey	Applicant
US5411540(A)	1995-05-01	Edell	Applicant
US5417719(A)	1995-05-01	Hull	Applicant
US5423864(A)	1995-06-01	Ljungstroem	Applicant
US5441528(A)	1995-08-01	Chang et al.	Applicant
US5464446(A)	1995-11-01	Dreessen et al.	Applicant
US5520190(A)	1996-05-01	Benedict et al.	Applicant
US5522864(A)	1996-06-01	Wallace et al.	Applicant
US5537512(A)	1996-07-01	Hsia	Applicant
US5540734(A)	1996-07-01	Zabara	Applicant
US5540736(A)	1996-07-01	Haimovich	Applicant
US5549655(A)	1996-08-01	Erickson	Applicant
US5562708(A)	1996-10-01	Combs et al.	Applicant
US5575813(A)	1996-11-01	Edell et al.	Applicant
US5591216(A)	1997-01-01	Testerman	Applicant
US5593432(A)	1997-01-01	Crowther et al.	Applicant
US5601611(A)	1997-02-01	Fayram et al.	Applicant
US5611350(A)	1997-03-01	John	Applicant
US5618531(A)	1997-04-01	Cherksey	Applicant
US5628317(A)	1997-05-01	Starkebaum	Applicant
US5674251(A)	1997-10-01	Combs et al.	Applicant
US5676655(A)	1997-10-01	Howard, III et al.	Applicant
US5683422(A)	1997-11-01	Rise	Applicant
US5702429(A)	1997-12-01	King	Applicant
US5707334(A)	1998-01-01	Young	Applicant
US5711316(A)	1998-01-01	Elsberry	Applicant
US5713922(A)	1998-02-01	King	Applicant
US5713923(A)	1998-02-01	Ward	Applicant
US5716377(A)	1998-02-01	Rise	Applicant
US5722401(A)	1998-03-01	Pietroski	Applicant
US5735814(A)	1998-04-01	Elsberry	Applicant
US5750376(A)	1998-05-01	Weiss et al.	Applicant
US5752979(A)	1998-05-01	Benabid	Applicant
US5769778(A)	1998-06-01	Abrams et al.	Applicant
US5772591(A)	1998-06-01	Cram	Applicant
US5782798(A)	1998-07-01	Rise	Applicant
US5782873(A)	1998-07-01	Collins	Applicant
US5792186(A)	1998-08-01	Rise	Applicant
US5797970(A)	1998-08-01	Pouvreau	Applicant
US5814014(A)	1998-09-01	Elsberry	Applicant
US5814092(A)	1998-09-01	King	Applicant
US5824021(A)	1998-10-01	Rise	Applicant
US5824030(A)	1998-10-01	Yang et al.	Applicant
US5832932(A)	1998-11-01	Elsberry	Applicant
US5833709(A)	1998-11-01	Rise	Applicant
US5843148(A)	1998-12-01	Gijsbers	Applicant
US5843150(A)	1998-12-01	Dressen	Applicant
US5865842(A)	1999-02-01	Knuth et al.	Applicant
US5871517(A)	1999-02-01	Abrams et al.	Applicant
US5885976(A)	1999-03-01	Sandyk	Applicant
US5886769(A)	1999-03-01	Zolten	Applicant
US5893883(A)	1999-04-01	Torgerson	Applicant
US5904916(A)	1999-05-01	Hirsch	Applicant
US5913882(A)	1999-06-01	King	Applicant
US5916171(A)	1999-06-01	Mayevsky	Applicant
US5925070(A)	1999-07-01	King	Applicant
US5928144(A)	1999-07-01	Real	Applicant
US5938688(A)	1999-08-01	Schiff	Applicant
US5938689(A)	1999-08-01	Fischell	Applicant
US5941906(A)	1999-08-01	Barreras	Applicant
US5964794(A)	1999-10-01	Bolz	Applicant
US5975085(A)	1999-11-01	Rise	Applicant
US5978702(A)	1999-11-01	Ward	Applicant
US5983140(A)	1999-11-01	Smith	Applicant
US6006124(A)	1999-12-01	Fischell	Applicant
US6011996(A)	2000-01-01	Gielen	Applicant
US6016449(A)	2000-01-01	Fischell	Applicant
US6018682(A)	2000-01-01	Rise	Applicant
US6021352(A)	2000-02-01	Christopherson	Applicant
US6026326(A)	2000-02-01	Bardy	Applicant
US6035236(A)	2000-03-01	Jarding et al.	Applicant
US6040180(A)	2000-03-01	Johe	Applicant
US6042579(A)	2000-03-01	Elsberry	Applicant
US6052624(A)	2000-04-01	Mann	Applicant
US6055456(A)	2000-04-01	Gerber	Applicant
US6057846(A)	2000-05-01	Sever, Jr.	Applicant
US6057847(A)	2000-05-01	Jenkins	Applicant
US6058331(A)	2000-05-01	King	Applicant
US6060048(A)	2000-05-01	Cherksey	Applicant
US6061593(A)	2000-05-01	Fischell	Applicant
US6066163(A)	2000-05-01	John	Applicant
US6095148(A)	2000-08-01	Shastri et al.	Applicant
US6104956(A)	2000-08-01	Naritoku	Applicant
US6104960(A)	2000-08-01	Duysens	Applicant
US6122548(A)	2000-09-01	Starkebaum	Applicant
US6126657(A)	2000-10-01	Edwards	Applicant
US6128527(A)	2000-10-01	Howard, III	Applicant
US6128537(A)	2000-10-01	Rise	Applicant
US6128538(A)	2000-10-01	Fischell	Applicant
US6134474(A)	2000-10-01	Fischell	Applicant
US6152143(A)	2000-11-01	Edwards	Applicant
US6161044(A)	2000-12-01	Silverstone	Applicant
US6161045(A)	2000-12-01	Fischell	Applicant
US6176242(B1)	2001-01-01	Rise	Applicant
US6418344(B1)	2001-01-01	Rezai	Applicant
US6190893(B1)	2001-02-01	Shastri et al.	Applicant
US6198958(B1)	2001-03-01	Ives et al.	Applicant
US6205360(B1)	2001-03-01	Carter et al.	Applicant
US6210417(B1)	2001-04-01	Baudino et al.	Applicant
US6221908(B1)	2001-04-01	Kilgard et al.	Applicant
US6230049(B1)	2001-05-01	Fischell et al.	Applicant
US6236892(B1)	2001-05-01	Feler	Applicant
US6246912(B1)	2001-06-01	Sluijter et al.	Applicant
US6263225(B1)	2001-07-01	Howard, III	Applicant
US6264944(B1)	2001-07-01	Smith	Applicant
US6280462(B1)	2001-08-01	Hauser et al.	Applicant
US6301493(B1)	2001-10-01	Marro et al.	Applicant
US6304787(B1)	2001-10-01	Kuzma et al.	Applicant
US6319241(B1)	2001-11-01	King et al.	Applicant
US6459936(B2)	2001-12-01	Fischell	Applicant
US6339725(B1)	2002-01-01	Naritoku et al.	Applicant
US6353754(B1)	2002-03-01	Fischell	Applicant
US6354299(B1)	2002-03-01	Frischell	Applicant
US6356792(B1)	2002-03-01	Errico	Applicant
US6360122(B1)	2002-03-01	Fischell	Applicant
US6366813(B1)	2002-04-01	DiLorenzo	Applicant
US6375666(B1)	2002-04-01	Mische	Applicant
US6687525(B2)	2002-05-01	Llinas	Applicant
US6405079(B1)	2002-06-01	Ansarinia	Applicant
US6427086(B1)	2002-07-01	Fischell	Applicant
US6456886(B1)	2002-09-01	Howard, III et al.	Applicant
US6463328(B1)	2002-10-01	John	Applicant
US6464356(B1)	2002-10-01	Sabel	Applicant
US6466822(B1)	2002-10-01	Pless	Applicant
US6473639(B1)	2002-10-01	Fischell	Applicant
US6480743(B1)	2002-11-01	Kirkpatrick	Applicant
US6484059(B2)	2002-11-01	Gielen	Applicant
US6487450(B1)	2002-11-01	Chen	Applicant
US6499488(B1)	2002-12-01	Hunter et al.	Applicant
US6505075(B1)	2003-01-01	Weiner	Applicant
US6507755(B1)	2003-01-01	Gozani et al.	Applicant
US6529774(B1)	2003-03-01	Greene	Applicant
US6539263(B1)	2003-03-01	Schiff et al.	Applicant
US6549814(B1)	2003-04-01	Strutz et al.	Applicant
US6556868(B2)	2003-04-01	Naritoku et al.	Applicant
US6569654(B2)	2003-05-01	Shastri et al.	Applicant
US6591138(B1)	2003-07-01	Fischell et al.	Applicant
US6597954(B1)	2003-07-01	Pless et al.	Applicant
US6615065(B1)	2003-09-01	Barrett et al.	Applicant
US6622048(B1)	2003-09-01	Mann	Applicant
US6633780(B1)	2003-10-01	Berger	Applicant
US6647296(B2)	2003-11-01	Fischell et al.	Applicant
US6658299(B1)	2003-12-01	Dobelle	Applicant
US6665562(B2)	2003-12-01	Gluckman et al.	Applicant
US6684105(B2)	2004-01-01	Cohen et al.	Applicant
US6690974(B2)	2004-02-01	Archer et al.	Applicant
US6708064(B2)	2004-03-01	Rezai	Applicant
US6725094(B2)	2004-04-01	Saberski	Applicant
US6764498(B2)	2004-07-01	Mische	Applicant
US6782292(B2)	2004-08-01	Whitehurst	Applicant
US6788975(B1)	2004-09-01	Whitehurst et al.	Applicant
US6795737(B2)	2004-09-01	Gielen et al.	Applicant
US6810286(B2)	2004-10-01	Donovan et al.	Applicant
US6839594(B2)	2005-01-01	Cohen et al.	Applicant
US6873872(B2)	2005-03-01	Gluckman et al.	Applicant
US6892097(B2)	2005-05-01	Holsheimer	Applicant
US6895280(B2)	2005-05-01	Meadows et al.	Applicant
US6907296(B1)	2005-06-01	Doan et al.	Applicant
US6934580(B1)	2005-08-01	Osorio et al.	Applicant
US6944497(B2)	2005-09-01	Stypulkowski	Applicant
US6944501(B1)	2005-09-01	Pless	Applicant
US6959215(B2)	2005-10-01	Gliner et al.	Applicant
US6990377(B2)	2006-01-01	Gliner et al.	Applicant
US7006859(B1)	2006-02-01	Osorio et al.	Applicant
US7010351(B2)	2006-03-01	Firlik et al.	Applicant
US7024247(B2)	2006-04-01	Gliner et al.	Applicant
US7107097(B2)	2006-09-01	Stern et al.	Applicant
US7110820(B2)	2006-09-01	Tcheng et al.	Applicant
US7184840(B2)	2007-02-01	Stolz et al.	Applicant
US2002/0028072(A1)	2002-03-01	Kashiyama	Applicant
US2002/0091419(A1)	2002-07-01	Firlik et al.	Applicant
US2002/0099412(A1)	2002-07-01	Fischell	Applicant
US2002/0138101(A1)	2002-09-01	Suda et al.	Applicant
US2002/0169485(A1)	2002-11-01	Pless	Applicant
US2003/0074032(A1)	2003-04-01	Gliner	Applicant
US2003/0078633(A1)	2003-04-01	Firlik et al.	Applicant
US2003/0088274(A1)	2003-05-01	Gliner et al.	Applicant
US2003/0097161(A1)	2003-05-01	Firlik et al.	Applicant
US2003/0125772(A1)	2003-07-01	Olson et al.	Applicant
US2003/0130706(A1)	2003-07-01	Sheffield et al.	Applicant
US2003/0149457(A1)	2003-08-01	Tcheng et al.	Applicant
US2003/0176901(A1)	2003-09-01	May	Applicant
US2003/0187490(A1)	2003-10-01	Gliner	Applicant
US2003/0187491(A1)	2003-10-01	Greenberg et al.	Applicant
US2003/0195602(A1)	2003-10-01	Boling	Applicant
US2004/0073270(A1)	2004-04-01	Firlik et al.	Applicant
US2004/0082847(A1)	2004-04-01	McDermott	Applicant
US2004/0088024(A1)	2004-05-01	Firlik et al.	Applicant
US2004/0092809(A1)	2004-05-01	DeCharms	Applicant
US2004/0102828(A1)	2004-05-01	Lowry et al.	Applicant
US2004/0111127(A1)	2004-06-01	Gliner et al.	Applicant
US2004/0131998(A1)	2004-07-01	Marom et al.	Applicant
US2004/0138550(A1)	2004-07-01	Hartlep et al.	Applicant
US2004/0158298(A1)	2004-08-01	Gliner et al.	Applicant
US2004/0176831(A1)	2004-09-01	Gliner et al.	Applicant
US2004/0181263(A1)	2004-09-01	Balzer et al.	Applicant
US2004/0215287(A1)	2004-10-01	Swoyer et al.	Applicant
US2004/0236388(A1)	2004-11-01	Gielen et al.	Applicant
US2004/0243205(A1)	2004-12-01	Keravel et al.	Applicant
US2004/0249422(A1)	2004-12-01	Gliner et al.	Applicant
US2005/0004620(A1)	2005-01-01	Singhal et al.	Applicant
US2005/0015129(A1)	2005-01-01	Mische	Applicant
US2005/0021104(A1)	2005-01-01	DiLorenzo	Applicant
US2005/0021105(A1)	2005-01-01	Firlik et al.	Applicant
US2005/0021106(A1)	2005-01-01	Firlik et al.	Applicant
US2005/0021107(A1)	2005-01-01	Firlik et al.	Applicant
US2005/0021118(A1)	2005-01-01	Genau et al.	Applicant
US2005/0033378(A1)	2005-02-01	Sheffield et al.	Applicant
US2005/0070971(A1)	2005-03-01	Fowler et al.	Applicant
US2005/0075679(A1)	2005-04-01	Gliner et al.	Applicant
US2005/0075680(A1)	2005-04-01	Lowry et al.	Applicant
US2005/0096701(A1)	2005-05-01	Donovan et al.	Applicant
US2005/0113882(A1)	2005-05-01	Cameron et al.	Applicant
US2005/0119712(A1)	2005-06-01	Shafer	Applicant
US2005/0154425(A1)	2005-07-01	Boveja et al.	Applicant
US2005/0154426(A1)	2005-07-01	Boveja et al.	Applicant
US2005/0182453(A1)	2005-08-01	Whitehurst	Applicant
US2006/0015153(A1)	2006-01-01	Gliner et al.	Applicant
US2006/0106430(A1)	2006-05-01	Fowler et al.	Applicant
US2006/0106431(A1)	2006-05-01	Wyler et al.	Applicant
US2006/0129205(A1)	2006-06-01	Boveja et al.	Applicant
US2006/0173522(A1)	2006-08-01	Osorio	Applicant
US2006/0217782(A1)	2006-09-01	Boveja et al.	Applicant
US2006/0241717(A1)	2006-10-01	Whitehurst et al.	Examiner
US2007/0088403(A1)	2007-04-01	Wyler	Applicant
DE19750043	1999-05-01		Applicant
EP214527	1987-03-01		Applicant
EP319844(A1)	1989-06-01		Applicant
EP998958(A2)	2000-10-01		Applicant
EP1145736	2001-10-01		Applicant
EP1180056	2003-11-01		Applicant
WO87/07511	1987-12-01		Applicant
WO-87-07511	1987-12-01		Applicant
WO94/07564	1994-04-01		Applicant
WO95/21591	1995-08-01		Applicant
WO-95-21591	1995-08-01		Applicant
WO97-45160	1997-12-01		Applicant
WO-98-06342	1998-02-01		Applicant
WO1/97906	2001-12-01		Applicant
WO-02-09811	2002-02-01		Applicant
WO2/09811	2002-02-01		Applicant
WO-02-36003	2002-05-01		Applicant
WO2/36003	2002-05-01		Applicant
WO2/38031	2002-05-01		Applicant
WO2/38217	2002-05-01		Applicant
WO-03-082402	2003-03-01		Applicant
WO-03-043690	2003-05-01		Applicant

Non-Patent Literature (169)

U.S. Appl. No. 60/325,872, Sheffield.Applicant
U.S. Appl. No. 60/325,978, Gliner.Applicant
American Heritage Dictionary, Hougton Mifflin Co., Boston, pp. 824.Applicant
Oliveri et al., “Paired transcranial magnetic stimulation protocols reveal a pattern of inhibition and facilitation in the human parietal cortex,” The Journal of Physiology, 529.2, pp. 461-468 (2000).Applicant
Levy et al., “Functional MRI Evidence of Cortical Reorganization in Upper-Limb Stroke Hemiplegia Treated with Constraint-Induced Movement Therapy,” American Journal of Physical Medicine & Rehabilitation, vol. 80, No. 1, pp. 4-7 (2001).Applicant
Cramer, S.C. and Bastings, E.P., “Mapping clinically relevant plasticity after stroke,” Neuropharmacology vol. 19, No. 5, pp. 842-851 (Apr. 2000).Applicant
Nitsche, M.A. and Paulus, W., “Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation,” The Journal of Physiology, vol. 527.3, pp. 663-639 (2000).Applicant
Cincotta et al., “Reorganization of the motor cortex in a patient with congenital hemiparesis and mirror movements,” Neurology, vol. 55, pp. 129-131 (2000).Applicant
Feys et al., “Value of somatosensory and motor evoked potentials in predicting arm recovery after a stroke,” (Oct. 1999).Applicant
Martinez et al., “Motor hand recovery after stroke Prognostic yield of early transcranial magnetic stimulation,” Electromyography. Clin. Neurophysiology, vol. 39, pp. 405-410 (1999).Applicant
Malenka, R.C. and Nicoll, R.A., “Long-Term Potenetiation—A Decade of Progress?,” Neuroscience, vol. 285, No. 5435, Issue of Sep. 17, 1999, pp. 1870-1874.Applicant
Franzini et al., “Reversal of thalamic hand syndrome by long-term motor cortex stimulation,” Journal of Neurosurgery 93:873-875 (2000).Applicant
Netz et al., “Reorganization of motor output in the non-affected hemisphere after stroke,” Brain, 120, pp. 1579-1586 (1997).Applicant
Sanes, J. and Donoghue, J.P. “Plasticity and Primary Motor Cortex,” Annual Review of Neuroscience 23:393-415 (2000).Applicant
Dam et al., “Effects of Fluoxetine and Maprotiline on Functional Recovery in Poststroke Hemiplegic Patients Undergoing Rehabilitation Therapy,” Stroke, vol. 27, No. 7, pp. 1211-1214 (Jul. 1996).Applicant
Kopell et al., “The Continuing Evolution of Psychiatric Neurosurgery,” CNS Spectrums, vol. 5, No. 10, pp. 20-31 (Oct. 2000).Applicant
Turton et al., “Contralateral and ipsilateral EMG responses to transcranial magnetic stimulation during recovery of arm and hand function after stroke,” Electroencephalography and Clinical Neurophysiology 101 pp. 316-328 (1996).Applicant
Van Der Lee et al., “The Intra- and Interrater Reliability of the Action Research Arm Test: A Practical Test of Upper Extremity Function in Patients With Stroke,” Arch. Phys. Med. Rehabil., vol. 82 pp. 14-19 (Jan. 2001).Applicant
Ziemann et al., “Modulation of Plasticity in Human Motor Cortex after Forearm Ischemic Nerve Block,” The Journal of Neuroscience 18(3):1115-1123 (Feb. 1998).Applicant
Cohen et al., “Studies of Neuroplasticity With Transcranial Magnetic Stimulation,” The Journal of Clinical Neurophysiology, vol. 15, No. 4 (1998).Applicant
Liepert et al., “Treatment-Induced Cortical Reorganization After Stroke in Humans,” Stroke, 31:1210-1216 (2000).Applicant
Gladstone et al., “Enhancing Recovery after Stroke with Noradrenergic Pharmacotherapy: A New Frontier?,” Can J. Neurol. Sci., vol. 27, No. 2 (May 2000).Applicant
Pascual-Leone et al., “Transcranial magnetic stimulation and neuroplasticity,” Neurophycologia 37, pp. 207-217 (1999).Applicant
Canavero, S. and Paolotti, R., “Extradural Motor Cortex Stimulation afor Advanced Parkinson's Disease: Case Report,” Movement Disorders, 15(1):169-171,2000.Applicant
International Search Report for Application No. PCT/US02/32695; Applicant: Vertis Neuroscience, Inc.; Dec. 27, 2002; 9 pgs; European Patent Office.Applicant
International Search Report for Application No. PCT/US02/07077; Applicant: Vertis Neuroscience, Inc., Oct. 22, 2002, 7 pgs.Applicant
Stefan et al., “Induction of plasticity in the human motor cortex by paired associative stimulation,” Brain, 123, pp. 572-584 (2000).Applicant
Pascual-Leone et al., “Study and Modulation of Human Cortical Excitability With Trancranial Magnetic Stimulation,” Journal of Clinical Neurophysiology, vol. 15, No. 4 (1998).Applicant
Schiff et al., “A neuromodulation strategy for rational therapy of complex brain injury states,” Neurological Research, vol. 22 pp. 267-272 (Apr. 2000).Applicant
Shimizu et al., “Therapeutic efficacy of transcranial magnetic stimulation for hereditary spinocerebellar degeneration,” Tohoku Journal of Experimental Medicine, 189(3):203-11 (Nov. 1999).Applicant
Roux et al., “Chronic Motor Cortex Stimulation for Phantom Limb Pain: A Functional Magnetic Resonance Imagining Study: Technical Cast Report,” Neurosurgery, vol. 49, No. 3 (Mar. 2001).Applicant
Kauhanen et al., “Domans and Determinants of Quality of Life After Stroke Caused by Brian Infarction,” Arch. Phys. Med. Rehabil., vol. 81, pp. 1541-1546 (Dec. 2000).Applicant
Butefisch et al., “Mechanisms of use-dependent plasticity in the human motor cortex,” Proc. Natl. Acad. Sci. USA, vol. 97, No. 7, pp. 3661-3665 (Mar. 2000).Applicant
Rezai, “Neurostimulation,” Neurological Research, vol. 22, No. 3 pp. 235-273 (Apr. 2000).Applicant
Bel, S. and Bauer, B.L., “Dorsal Column Stimulation (DCS): Cost to Benefit Analysis,” Acta Neurochirurgica, Suppl. 52, pp. 121-123 (1991).Applicant
Sandkuhler, “Learning and memory in pain pathways,” Pain 88, pp. 113-118 (2000).Applicant
Sanes, “The Relation between Human Brain Activity and Hand Movements,” NeuroImage 11, pp. 370-374 (2000).Applicant
Walker-Batson et al., “Amphetamine Paired With Physical Therapy Accelerates Motor Recovery After Stroke,” Stroke, vol. 26, No. 12, pp. 2254-2259 (1995).Applicant
Sanes, J.N. and Donoghue, J.P., “Plasticity and Primary Motor Cortex,” Annu. Rev. Neurosci. 23:393-415 (2000).Applicant
Saitou et al., “Cerebral Blood Volume and Oxygenation Among Poststroke Hemiplegic Patients: Effects of 13 Rehabilitation Tasks Measured by Near-Infrared Spectroscopy,” Arch. Phys. Med. Rehabil., vol. 81 pp. 1348-1356 (Oct. 2000).Applicant
Turton, A. and Lemon, R.N., “The contribution of fast corticospinal input to the voluntary activation of proximal muscles in normal subjects and in stroke patients,” Exp. Brain Res., vol. 129, pp. 559-572 (1999).Applicant
Stefan et al., “Introduction of plasticity in the human motor cortex by paired associative stimulation,” Brian, vol. 123, No. 3, pp. 575-584 (Mar. 2000).Applicant
Rossi et al., “Effects of Repetitive Transcranial Magnetic Stimulation on Movement-related Cortical Activity in Humans,” Cerebral Cortex, vol. 10, No. 8, pp. 802-808 (Aug. 2000).Applicant
Hodge, Jr., C.J. and Boakye, M., “Biological Plasticity: The Future of Science in Neurosurgery,” Neurosurgery, vol. 48, No. 1 (Jan. 2001).Applicant
Gordon et al., “Parameters for direct cortical electrical stimulation in the human: histopathologic confirmation,” Electroencephalography and clinical Neurophysiology, vol. 75, pp. 371-377 (1990).Applicant
Classen et al., “Rapid Plasticity of Human Cortical Movement Representation Induced by Practice,” The Journal of Neurophysiology, vol. 79, No. 2, pp. 1117-1123 (Feb. 1998).Applicant
Ziemann et al., “Modulation of Plasticity in Human Motor Cortex after Forearm Ischemic Nerve Block,” The Journal of Neuroscience, vol. 18, No. 3, pp. 1115-1123 (Feb. 1998).Applicant
Siebner et al., “Lasting cortical activation after repetitive TMS of the motor cortex,” NEUROLOGY 54, pp. 956-963 (Feb. 2000).Applicant
Barr, Deborah et al., “Induction and Reversal of Long-Term Potentiation by Low-and High-Intensity Theta Pattern Stimulation,” The Journal of Neuroscience, 15(7): pp. 5402-5410 (Jul. 1995).Applicant
Benabid, A.L. et al, “Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders,” J. Neurosurg., Apr. 1997, 86(4); 737; http:—www.ncbi.nlm.nih.gov; [accessed Nov. 18, 2003].Applicant
Blustone, Avraham Y. et al., “Three-dimensional optical tomography of hemodynamics in the human head,” Optics Express, vol. 9, No. 6, pp. 272-286 (Sep. 10, 2001).Applicant
Brain Electrical Stimulation to Enhance Recovery After Stroke. ClinicalTrials.gov. [Retrieved on Dec. 22, 2005]. Retrieved from the internet <URL http:—www.clinicaltrials.gov-ct-show-NCT00085657?order=2>.Applicant
Burnett, Mark G. et al., “Diffuse optical measurement of blood flow, blood oxygenation, and metabolism in a human brain during sensorimotor cortex activation,” Optics Letters, vol. 29, No. 15, pp. 1766-1768 (Aug. 1, 2004).Applicant
Bury, Scott et al., “The Effects of Behavioral Demand on Motor Cortical and Cerebellar Structural Plasticity After Brain Injury in Adult Rats,” [Retrieved on Mar. 1, 2003]. Retrieved from the internet: <URL: http:—www.mcmaster.ca.inabis98-schallert-bury0827-index.html>.Applicant
Canavero, S. and Paolotti, R., “Extradural Motor Cortex Stimulation for Advanced Parkinson's Disease: Case Report,” Movement Disorders 15(1): 160-171, 2000.Applicant
Cao, Yue et al., “Cortical Language Activiation in Stroke Patients Recovering From Aphasia With Functional MRI,” Stroke, vol. 30, pp. 2331-2340, Nov. 1999.Applicant
Classen, et al., “Rapid Plasticity of Human Cortical Movement Representation Induced by Practice,” The Journal of Neurophysiology, vol. 79, No. 2, pp. 1117-1123 (Feb. 1998).Applicant
Cytokines Web Clinical Significance. Cytokines Web, 2 pages. [Retrieved on Sep. 2, 2005]. Retrieved from the internet: <URL: <http:—cmbi.bjmu.edu.cn-cmbidata-cgf-CGF—Database-cytweb-roles-index.html>>.Applicant
De Ridder, Dirk et al., “Magnetic and electrical stimulation of the auditory cortex for intractable tinnitus,” Journal Neurosurg., vol. 100, pp. 560-564, (Mar. 2004).Applicant
Di Lazzaro, V. et al., “Theta-beta repetitive transcranial magnetic stimulation suppressess specific excitatory circuits in the human motor cortex,” Physiology in Press; published online on Apr. 21, 2005 as 10.1113-jphysio.2005.087288.Applicant
Ding, Yuemin et al., “Neural Plasticity After Spinal Cord Injury,” Current Pharmaceutical Design vol. 11, No. 11, pp. 1441-1450, Abstract Only- 1 page (Apr. 2005).Applicant
Duncan, Pamela W. et al., “Designing post-stroke recovery: implications for design and interpretation of drug trials,” Neuropharmacology vol. 39, pp. 835-841 (2000).Applicant
Hagemann, Georg et al., “Increased Long-Term Potentiation in the Surround of Experimentally Induced Focal Cortical Infarction,” Annals of Neurology, vol. 44, No. 2, pp. 255-258 (Aug. 1998).Applicant
Hayakawa, Toshiji et al., “Changes in Cerebral Oxygenation and Hemodynamics During Obstructive Sleep Apneas,” Chest, vol. 109, pp. 916-921 (1996).Applicant
Hoshi, Yoko et al., “Detection of dynamic changes in cerebral oxygenation coupled to neuronal function during mental work in a man,” Neuroscience Letters, vol. 150, pp. 5-8 (1993).Applicant
Hoshino et al., “Application of multichannel near-infrared spectroscopic topography to physiological monitoring of the cortex during cortical mapping: technical case report,” Surgical Neurology, vol. 64, pp. 272-275 (2005).Applicant
How Imagent™ Works. ISS Inc., 1 page [Retrieved on Oct. 14, 2005]. Retrieved from the internet: <URL http:—www.iss.com-Products-imagent—fmri.html>.Applicant
Huang, Ying-Zu et al., “Theta Burst Stimulation of the Human Motor Cortex,” Neuron, vol. 45, pp. 201-206 (Jan. 20, 2005).Applicant
Hummel, Friedhelm et al., “Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke,” Brain Advance Access, Jan. 5, 2005, pp. 1-10, Brain.Applicant
Imagent™ Functional Brain Imaging System. ISS, Inc., 2 pages [Retrieved on Oct. 14, 2005]. Retrieved from the internet: <URL http:—www.iss.com-Products-imagent.html>.Applicant
Imagent™ functional Near Infrared Imaging System (fNIRS) Brain Imaging Using Infrared Photons. ISS Inc., 8 pages [Retrieved on Oct. 14, 2005]. Retrieved from the internet: <URL http:—www.iss.com-products-imagent-Imagent™.pdf>.Applicant
International Search Report for PCT-US03-38986; May 2004; Applicant: Northstar Neuroscience, Inc. (7 pgs).Applicant
Janicek, Milos J. et al., “Dynamic Infrared Imaging of Newly Diagnosed Malignant Lymphoma Compared with Gallium-67 and Fluorine-18 Fluorodeoxyglucose (FDG) Positron Emission Tomography,” Technology in Cancer Research and Treatment, vol. 2, No. 6, pp. 571-577 (Dec. 2003).Applicant
Keyvani, Kathy et al., “Suppression of proteasome C2 contralateral to ischemic lesions in rat brain,” Brain Research, vol. 858, pp. 386-392, 2000.Applicant
Kilgard, Michael et al., “Cortical Map Reorganization Enabled by Nucleus Basalis Activity,” Science, vol. 279, pp. 1714-1717 (Mar. 13, 1998).Applicant
Lang, Nicolas et al., “Preconditioning with Transcranial Direct Current Stimulation Sensitizes the Motor Cortex to Rapid-Rate Transcranial Magnetic Stimulation and Controls the Direction of After-Effects,” Biol Psychiatry 2004:56:634-639, 2004 Society of Biological Psychiatry.Applicant
Larson, John et al., “Reversal of LTP by theta frequency stimulation,” Brain Research, 600: pp. 97-102 (1993).Applicant
Lazar, M. et al., “White Matter Tractography Using Diffusion Tensor Deflection,” Human Brain Mapping, 18:306-321, (2003).Applicant
L-DOPA dyskinesias. BioChemistry of PD. [Retrieved on Dec. 22, 2005]. Retrieved from the internet <URL http:—www.mayo.edu-fdp-pd-info-dyskinesias.htm>.Applicant
Mansur, C.G., et al., “A sham stimulation-controlled trial of rTMS of the unaffected hemispehere in stroke patients,” Neurology, vol. 64, pp. 1802-1804 (2005).Applicant
Martin et al, “Transcranial Magnetic Stimulation as a Complementary Treatment for Aphasia,” Semin Speech Language, vol. 25, pp. 181-191 (2004) Abstract Only- 1 page.Applicant
Meyerson, B.A. et al., “Motor Cortex Stimulation as Treatment of Trigeminal Neuropathic Pain”, Acta Neurochirurgica Supplementum, vol. 58, pp. 150-153 (1993).Applicant
Nitsche, Michael A. et al., “Level of action of cathodal DC polarisation induced inhibition of the human motor cortex,” Dec. 2, 2002, Clinical Neurophysiology 114 (2003) 600-604.Applicant
Nitsche, Michael A., et al. “Facilitation of Implicit Motor Learning by Weak Transcranial Direct Current Stimulation of the Primary Motor Cortex in the Human,” Journal of Cognitive Neuroscience 15:4, pp. 619-626, 2003 Massachusetts Institute of Technology.Applicant
Nudo, Randolph J., et al., “Recovery after damage to motor cortical areas,” Current Opinion in Neurobiology, vol. 9, Issue 6, pp. 740-747, Dec. 1, 1999.Applicant
Panchanathan, Sethuraman et al., “Rehabilitation of patients with hemispatial neglect using visual-haptic feedback in Virtual reality environment,” [Retrieved on Dec. 22, 2005]. Retrieved from the internet <http:—www.public.asu.edu-˜tmcdani-publications.htm>>.Applicant
Paulus, W, “Supplements to Clinical Neurophysiology,” Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation (Supplements to Clinical Neurophysiology; vol. 56), pp. 249-254, 2003 Elsevier Science, B.V.Applicant
Paulus, Walter, “Toward Establishing a Therapeutic Window for rTMS by Theta Burst Stimulation,” Neuron, vol. 45, pp. 181-183 (Jan. 20, 2005).Applicant
Penn, Michael, “Stemming Parkinson's,” on Wisconsin Alumni Magazine, Summer 2003, [Retrieved on Dec. 22, 2005]. Retrieved from the internet <URL http:—www.uwalumni.com-onwisconsin-2003—summer-research.html>.Applicant
Schaefer, Pamela W. et al., “Assessing Tissue Viability with MR Diffusion and Perfusion Imaging,” AJNR, 24: pp. 436-443 (Mar. 2003).Applicant
Schiene, Klaus et al., “Neuronal Hyperexcitability and Reduction of GABA-Receptor Expression in the Surround of Cerebral Photothrombosis,” Journal of Cerebral Blood Flow and Metabolism, vol. 16, No. 5, pp. 906-914 (1996).Applicant
SCIRun. Scientific Computing and Imaging Institute, 2 pages. [Retrieved on Jul. 4, 2005]. Retrieved from the internet: <URL: <http:—sofware.sci.utah.edu-scirun.html>>.Applicant
Strangman, Gary et al., “A Quantitative Comparison of Simultaneous BOLD fMRI and NIRS Recordings during Functional Brain Activation,” NeuroImage, vol. 17, pp. 719-731 (2002).Applicant
Strangman, Gary et al., “Factors affecting the accuracy of near-infrared spectroscopy concentration calculations for focal changes in oxygenation parameters,” NeuroImage, vol. 18, pp. 865-879 (2003).Applicant
Strangman, Gary et al., “Non-Invasive Neuroimaging Using Near-Infrared Light,” Biological Psychiatry, vol. 52, pp. 679-693 (2002).Applicant
Strens, Lucy et al., “The Ipsilateral Human Motor Cortex Can Functionally Compensate for Acute Contralateral Motor Cortex Dysfunction,” Current Biology, vol. 13, pp. 1201-1205, Jul. 15, 2003.Applicant
Taga, Gentaro et al., “Brain imaging in awake infants by near-infrared optical topography,” PNAS, vol. 100, No. 19, pp. 10722-10727 (Sep. 16, 2003).Applicant
Tang, Cha-Min et al., “Optical Coherence Tomography of the Human Basal Ganglion,” Deep Brain Stimulation Consortium Meeting Program Book, Sep. 29-30, 2003, Washington DC.Applicant
The GES 250 for Dense-Array EEG Research. Electrical Geodesics, Inc., 3 pages. [Retrieved on Aug. 25, 2005]. Retrieved from the internet: <URL: http:—www.egi.com-ges250r—n.html>.Applicant
The INVOS Cerebral Oximeter. Somanetics, 1 page [Retrieved on Dec. 22, 2005]. Retrieved from the internet <URL <http:—www.somanetics.net-invos.htm>>.Applicant
Theoret, Hugo et al., “Exploring Paradoxical Functional Facilitation with TMS,” Supplements to Clinical Neurophysiology, vol. 56, pp. 211-219 (2003).Applicant
Thomas, Carmen et al., “Do Children with aggressive behavior have temporal lobe changes?” Alasbimn Journal, Year 5, No. 19, 8 pages (Jan. 2003).Applicant
Timmermann, Lars et al., “The cerebral oscillatory network of parkinsonian resting tremor,” Brain, vol. 26, pp. 199-212, (2003).Applicant
Toronov, Vlad et al., “Near-infrared study of fluctuations in cerebral hemodynamics during rest and motor stimulation: Temporal analysis and spatial mapping,” Medical Physics, vol. 27, No. 4, pp. 801-815 (Apr. 2000).Applicant
Tractography. Absolute Astronomy Reference, 2 pages. [Retrieved on Jul 24, 2005]. Retrieved from the internet: <URL: http:—www.absoluteastronomy.com-encyclopedia-T-Tr-Tractography.htm>.Applicant
Tsubokawa, T. et al., “Chronic Motor Cortex Stimulation for the Treatement of Central Pain”, Acta Neurochirurgica Supplementum, vol. 52, pp. 137-139 (1991).Applicant
Tsubokawa, T. et al., “Treatment of Thalamic Pain by Chronic Motor Cortex Stimulation”, PACE, vol. 14, pp. 131-134 (Jan. 1991).Applicant
Tsubokawa, T., “Chronic Motor Cortex Stimulation in Patients with Thalamic Pain,” J. Neurosurg 78:393-401, (Mar. 1993).Applicant
Tuch, D. et al., “Conductivity Tensor Mapping of the Human Brain Using Diffusion Tensor MRI,” Neurobiology, vol. 98, No. 20, pp. 11697-11701, Sep. 25, 2001.Applicant
Weinand, Martin E. et al., “Cerebral blood flow and temporal lobe epileptogenicity,” [Retrieved on Dec. 22, 2005]. Retrieved from the internet: <URL http:—www.aans.org-education-journal-neurosurgical-nov96-1-5-3.asp>.Applicant
Yokoh, Arika et al., “Intermittent versus continuous brain retraction,” Journal of Neurosurgery, vol. 58, pp. 918-923 (Jun. 1983).Applicant
U.S. Appl. No. 09/978,134, Gliner.Applicant
U.S. Appl. No. 10/742,579, Gliner.Applicant
U.S. Appl. No. 10/072,700, Firlik.Applicant
U.S. Appl. No. 10/731,892, Sheffield.Applicant
U.S. Appl. No. 10/583,630, filed Jun. 20, 2006, Lozano.Applicant
U.S. Appl. No. 11/254,060, filed Oct. 19, 2005, Wyler.Applicant
U.S. Appl. No. 11/255,187, filed Oct. 19, 2005, Firlik.Applicant
U.S. Appl. No. 11/344,453, filed Jan. 30, 2006, Gliner.Applicant
U.S. Appl. No. 11/518,139, filed Sep. 7, 2006, Weinand.Applicant
U.S. Appl. No. 11638,326, filed Dec. 12, 2006, Gliner et al.Applicant
U.S. Appl. No. 11/697,694, filed Apr. 6, 2007, Fowler.Applicant
U.S. Appl. No. 11/697,696, filed Apr. 6, 2007, Pascual-Leone.Applicant
U.S. Appl. No. 11/697,703, filed Apr. 6, 2007, Gaw.Applicant
Barres et al., “Proliferation of oligodendrocyte precursor cells depends on electrical activity in axons, ” Nature; Medical Research Council Developmental Neurobiology Programme, Department of Biology, University College, London, pp. 258-260, (Jan. 21, 1993).Applicant
Behrens, T. et al., “Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging, ” Nature neuroscience, vol. 6 No. 7, pp. 750-757 (jul.2003).Applicant
Beveridge, J.A., “Use of Exogenous Electric Current in the Treatment of Delayed Lesions in Peripheral Nerves,” Plastic and Reconstructive Surgery, Oct. 1998, vol. 82, No. 4, pp. 573-579.Applicant
Bezard et al., “Cortical Stimulation and Epileptic Seizure: A study of the Potential Risk in Primates,” Neurosurgery, vol. 45, No. 2, Aug. 1999, 346-350.Applicant
Binder, J.M.D., “Functional Magnetic Resonance Imaging: Language Mapping,” Neurosurgery Clinics of North America, vol. 8, No. 3, Jul. 1997, pp. 383-392.Applicant
Cheun et al., “Differential of a Stem Cell Line Toward a Neuronal Phenotype,” Int. J. Devl. Neuroscience, vol. 9, No. 4, pp. 391-404 (1991).Applicant
Cincinelli et al., “Transcranial magentic stimulation reveals an interhemispheric asymmetry of cortical inhibition in focal epilepsy,” Neurophysiology, vol. 11, No. 4 Mar. 20, 2000, pp. 701-707.Applicant
Cincotta et al., “Suprathreshold 0.3 Hz repetitive TMS prolongs the cortical silent period: potential implications for therapeutic trials in epilepsy, ” Clinical Neurophysiology, vol. 114, 2003, pp. 1827-1833, Elsevier Ireland Ltd.Applicant
CNN.com, Health, “Lab Zaps Strokes with Magnetic Pulses, ” http://www.cnn.com/2004/HEALTH/conditions/11/29/zapping.strokes.ap/, Nov. 29, 2004, 4 pages [Retrieved on Dec. 2, 2004].Applicant
Crammer et al., “Use of Functional MRI to Guide Decisions in a clinical Stroke Trial, ” Stroke, Journal of the American Heart Association, May 2005, pp. e50-e52, American Heart Association, Dallas TX.Applicant
Ferrari, A. et al., “Immature human NT2 cells grafted into a mouse brain differentiate into neuronal and glial cell types,” FEBS Letters, Dec. 8, 2000, pp. 121-125, vol. 486, No. 2, Elsevier Science B.V., Amsterdam.Applicant
Fregni et al., “Antiepileptic Effects of Repetitive Transcranial Magnetic Stimulation in Patients with Cortical Malformations: An EEG and Clinical Study,” ASSFN Proceedings 2004, Stereotactic and Functional Neurosurgery, 2005, 83:57-62.Applicant
Fregni, Felipe et al., “Anodal Transcranial Direct Current Stimulation of Prefrontal Cortex Enhances Working Memory,” Experimental Brain Research vol. 166, No. 1, pp: 23-30 (Sep. 2005).Applicant
Haglund, Michael M. et al., “Optical imaging of epileptiform and functional activity in human cerebral cortex,” Nature, Aug. 20, 1992, pp. 668-671, vol. 358, Nature Publishing Group.Applicant
Ishibashi, Tomoko et al., “Astrocytes Promote Myelination in Response to Electrical Impulses,” Neuron 49, pp. 823-832, (Mar. 16, 2006).Applicant
Kelly-Spratt, K. “Transfectional of PC-12 cells: a model system for primary neuronal cells,” Qiagen News, Customer application article, www.qiagen.com, Issue 4, 1998, 2 pages.Applicant
Kimura, K. et al., “Electrically induced neurite outgrowth of PC 12 cells on the electrode surface,” Published: Med. Bio. Eng. Comput., Jul. 1998, Abstract Only, 36(4):493-8, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=Abstract.Applicant
Kinoshita et al., “Electric cortical stimulation suppresses epileptic and background activities in neocortical epilepsy and mesial temporal lobe epilepsy,” Clinical Neurophysiology, vol. 116, 2005, pp. 1291-1299, Elsevier Ireland Ltd.Applicant
Kossoff et al., “Effect of an External Responsive Neurostimulator on Seizures and Electrographic Discharges during Subdural Electrode Monitoring,” Epilepsia 45(12):1560-1567, 2004, Blackwell Publishing, Inc.Applicant
Lutsep et al., “Safety of Cortical Stimulation in Patients with Hemiparetic Stroke, ” Oasis, Online Abstract Submission and Invitation System - Program Planner, International Stroke Conference 2005, 1 pages, American Stroke Association.Applicant
Mendonca, A.C., “Directly applied low intensity direct electric current enhances peripheral nerve regeneration in rats, ” Journal of Neuroscience Methods, 2003, vol. 129, pp. 183-190.Applicant
misawa et al., “Low-frequency transcranial magnetic stimulation for epilepsia partialis continua dut to cortical dyplasia,” Journal of the Neurological Sciences, vol. 234, 2005, pp. 37-39.Applicant
Montgomery, “Thalamic Stimulation,” Neuroscience Pathways, The Cleveland Clinic Foundation, 2 pages.Applicant
Motamedi et al., “optimizing Parameters for Terminating Cortical Afterdischarges with Pulse Stimulation,” Epilepsia 43(8):836-846, 2002, Blackwell Publishing, Inc.Applicant
Politis, M. J., “Mammalian Optic Nerve Regeneration Following the Application of Electric Fields,” The Journal of Trauma, Nov. 1998, vol. 28, No. 11, pp. 1548-1552.Applicant
Price, J. et al., “Neurotransplantation in neurodegenerative disease: a survey of relevant issues in developmental neurobiology,” Novartis Foundation Symposium 231, 2000, pp. 148-165, Wiley, Chichester, UK.Applicant
Robinson, Kenneth R., “The Responses of Cells to Electrical Fields: A Review,” The Journal of Cell Biology, vol. 101, pp. 2023-2027 (Dec. 1985).Applicant
Schulz et al., “Localization of Epileptic Auras Induced on Stimulation by Subdural Electrodes,” Epilepsia, Dec. 1997, vol. 38, Issue 12, pp.1321-1329.Applicant
Sioutos et al. Continuous Regional Cerebral Cortical Blood Flow Monitoring in Head-injured Patients, Neurosurgery, vol. 36, No. 5, May 1995, pp. 943-949.Applicant
Storer et al., “Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat,”Brain, 1997, vol.120, Issue 12, pp. 2171-2177, Oxford University Press.Applicant
Suzuki et al., “Selective Electrical Stimulation of Postganglionic Cerebrovascular Parasympathetic Nerve Fibers Originating from the Sphenopalatine Ganglion Enhances Cortical Blood Flow in the Rat,” Journal of Cerebral Blood Flow and Metabolism, May 1990, 10(3):383-91.Applicant
The National Institute of Health (NJN) Consensus Development Program, “Surgery for Epilepsy,” National Institutes of Health Consensus Development conference Statement, Mar. 19-21, 1990, 16 pages.Applicant
Velasco et al. “Absolute and Relative predictor Values of Some Non-Invasive and Invasive Studies for the Outcome of Anterior Temporal Lobectormy,” Science Direct, vol. 31, Issue 1, Jan.-Feb. 2000, pp. 62-74, Elsevier Science, Inc.Applicant
Velasco et al. “Acute and Chronic Electric Stimulation of the Centromedian Thalamic Nucleus: Modulation of Reticulo-Cortical Systems and Predictor Factors for Generalized Seizure Control,” Archives of Medical research, May-Jun., 2000, 31(3):304-315, Elsevier Science, Inc.Applicant
Velasco et al. “Electrical Stimulation for Epilepsy: Stimulation of Hippocampal Foci,” Proceedings of the 13th Meeting of the World Society and Functional Neurosurgery, vol. 77, No. 1-4, pp. 223-227.Applicant
Velasco et al. “Subacute and Chronic Electrical Stimulation of the Hippocampus on Intractable Temporal Lobe Seizures: Preliminary Report,” Archives of Medical Research, May-Jun., 2000, 31(3):316-28, Elsevier Science.Applicant
Velasco et al. “Subacute Electrical Stimulation of the HippocampusBlocks Intractable Temporal Lobe Seizures and Paroxysmal EEG Activities,” Epilepsia, Feb., 2000, 41(2):158-169, Lippincott Williams & Wilkins, Philadelphia.Applicant
Waxman et al., “The Interictal Behavior Syndrome of Temporal Lobe Epilepsy,” Arch Gen Psychiatry, vol. 32, Dec. 1975, pp. 1580-1586.Applicant
Weinand et al., “Cerebral blood flow and temporal lobe epileptogenicity,” J Neurosurg. vol. 86, Feb. 1997, pp. 226-232.Applicant
Weinand et al., “Cerebral blood flow and temporal lobe epileptogenicity,” Neurosurgical Focus, Nov. 1996, vol. 1, No. 5, AANS.ORG, http:www.aans.org/education/journal/neurosurgical/nov96/1-5-3.asp, 17 pages.Applicant
Weinand et al., Long-term ictal monitoring with subdural strip electrodes: prognostic factors for selecting temporal lobectomy candidates, J. Neurosurg, vol. 77, 1992, pp. 20-28.Applicant
Weinand et al., “Surface cortical cerebral blood flow monitoring and single photon emission computed tomography: prognostic factors for selecting temportal lobectormy candidates,” Seizure, vol. 3, 1994, pp. 55-59.Applicant
Weinand et al., “Targeted Subthreshold Cortical Stimulation for Recovery of Motor Hand Function following Hemiparetic Stroke,” Abstract: 2005 Apr. 18, AANS.org, http:www.aans.org/Library/Article.aspx?Articleld=24934, 2 pages.Applicant
Woodbury, D. et al., “Adult Rat and Human Bone Marrow Stromal Cells Differentiate Into Neurons,” Journal of Neuroscience Research, Aug. 15, 2000, 61(4):364-70, Wiley Interscience, New York, NY.Applicant
Yamamoto et al., “Low-frequency Electric Cortical Stimulation Has an Inhibitory Effect on Epileptic Focus in Mesial Temporal Lobe Epilepsy,” Epilepsia, vol. 43, No. 5, 2002, pp.291-295, Blackwell Publishing, Inc.Applicant

Abstract